Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Hematology
•
Neurology
•
Vascular Neurology
•
Neurohospitalist
What is the preferred approach to managing non-occlusive or partially occlusive venous sinus thrombosis?
Answer from: at Academic Institution
I would recommend a DOAC, particularly apixaban, with follow-up imaging in 3 months.
Comments
at Northside Hospital
Thank you, Dr. @Kirshner. If it remains stable/unc...
at Vanderbilt University Medical Center
I think this is a question for which there is no r...
11705
11721
Sign In
or
Register
to read more
20808
Related Questions
What is the utility of a hypercoagulability workup in recurrent cryptogenic stroke, and what specific tests would you recommend?
How long would you continue chronic transfusion therapy for adult sickle cell patients who have had a stroke?
What is your clinical threshold for treating a potential monoclonal gammopathy of thrombotic significance?
Would you offer TPO-RAs to a steroid-refractory chronic ITP patient with history of stroke?
Would you consider IV thrombolytics in patients with acute ischemic stroke, with or without a large vessel occlusion, if they have a history of von Willebrand disease (VWD), regardless of its type?
For stroke patients with ablated paroxysmal atrial fibrillation without known recurrence and ICAD, would you recommend dual antiplatelet therapy or anticoagulation with or without an antiplatelet agent?
Do you make any dose adjustments for patients with ESKD who are on apixaban and do not otherwise meet criteria for reduced dosing?
How would you approach the upfront management of a patient with acute unilateral vision loss with strong clinical risk factors for both cardioembolic stroke and GCA if an expedited MRI is not possible due to the presence of an AICD?
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
At what point should aspirin therapy for stable cardiovascular disease be discontinued in patients with a diagnosis of chronic cerebral microbleeds or possible Cerebral Amyloid Angiopathy?
Thank you, Dr. @Kirshner. If it remains stable/unc...
I think this is a question for which there is no r...